A recent U.S. Supreme Court ruling could give generic pharmaceutical companies greater protection from patent lawsuits, but Baton Rouge pharmaceutical executive Keith LaNasa says the decision doesn’t rewrite the rules governing how those companies bring drugs to market. The court on June 4 unanimously sided with Hikma Pharmaceuticals in its dispute with Amarin Pharma. At
Local pharma CEO says Hikma v. Amarin ruling brings clarity, not new opportunities
Sign up for the free Daily Report email – local news about the people, companies and issues that impact business impact business in Baton Rouge and beyond.
